Litigation (Details) (Pending Litigation [Member])	12 Months Ended
Dec. 31, 2014
Pending Litigation [Member]
Litigation
Maximum period for which the FDA is automatically precluded from approving Teva's ANDA	30 months

Represents the maximum period of time from receipt of a Notice Letter corresponding to a Abbreviated New Drug Application (ANDA) for which the FDA is precluded from approving the Abbreviated New Drug Application (ANDA), under the Hatch-Waxman Act.

No definition available.

Name:	uthr_LossContingencyPeriodForWhichLawsuitWouldPrecludeFDAFromApprovingANDA
Namespace Prefix:	uthr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration